SCHEDULE 13G/A: Halpern Trust Discloses 9.99% Stake in Eterna Therapeutics
Beneficial Ownership Report
John D. Halpern and Katherine H. Halpern, as trustees of the John D. Halpern Revocable Trust, have reported a 9.99% beneficial ownership stake in Eterna Therapeutics Inc. common stock.
Summary
- John D. Halpern and Katherine H. Halpern, acting as trustees of the John D. Halpern Revocable Trust, have filed an Amendment No. 4 to Schedule 13G concerning their beneficial ownership in Eterna Therapeutics Inc.
- They collectively beneficially own 5,136,581 shares of Eterna Therapeutics Inc. common stock.
- This ownership represents 9.99% of the company's total outstanding common stock.
- The reported ownership comprises 5,136,571 shares held directly by the John D. Halpern Revocable Trust and an additional 10 shares issuable upon the exercise of a Pre-Funded Common Stock Purchase Warrant.
- A blocker provision within the warrant prevents its exercise if it would result in beneficial ownership exceeding 9.99%, consequently excluding 114,990 additional shares from the currently reported ownership.
- The 9.99% ownership percentage is calculated based on an aggregate of 51,374,723 outstanding shares, which includes 51,374,713 shares reported in the Issuer's Quarterly Report on Form 10-Q filed on November 12, 2024, plus the 10 warrant shares deemed outstanding within 60 days.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine beneficial ownership disclosure and does not contain operational or financial performance information or indicate any significant change in strategy or control.
Positives
- The filing confirms a significant and stable ownership stake by the John D. Halpern Revocable Trust, indicating a long-term interest in Eterna Therapeutics Inc.
Risks
- The warrant includes a blocker provision that prevents the beneficial ownership from exceeding 9.99%, limiting the immediate full exercise of the warrant for an additional 114,990 shares.
Future Outlook
The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding Eterna Therapeutics Inc.'s operational or financial performance.
Industry Context
This filing is a routine disclosure of significant beneficial ownership and does not provide information related to broader industry trends, competitive landscape, or Eterna Therapeutics Inc.'s specific market position.
Stakeholder Impact
- This filing confirms a significant, stable ownership stake by the Halpern Trust, which may provide a sense of stability for other shareholders by indicating a committed long-term investor.
Key Dates
| Date | Description |
|---|---|
| 10/29/2024 | Date of event which required the filing of this statement (issuance of the Pre-Funded Common Stock Purchase Warrant). |
| 11/12/2024 | Date of the Issuer's Quarterly Report on Form 10-Q, which reported 51,374,713 shares of Common Stock outstanding. |
| 02/14/2025 | Signature date of the Schedule 13G Amendment No. 4 by John D. Halpern and Katherine H. Halpern. |
Keywords
Eterna Therapeutics, John D. Halpern, Katherine H. Halpern, Schedule 13G, beneficial ownership, common stock, SEC filing, investment, trust
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.